These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 12751815)
21. Computational study of the sulfonylated amino acid hydroxamates binding to the zinc ion within the active site of carbonic anhydrase. Sille J; Remko M J Biomol Struct Dyn; 2009 Feb; 26(4):431-44. PubMed ID: 19108582 [TBL] [Abstract][Full Text] [Related]
22. QSAR study on carbonic anhydrase inhibitors: aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties, with topical activity as antiglaucoma agents. Agrawal VK; Bano S; Supuran CT; Khadikar PV Eur J Med Chem; 2004 Jul; 39(7):593-600. PubMed ID: 15236839 [TBL] [Abstract][Full Text] [Related]
23. Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors. Di Fiore A; Maresca A; Supuran CT; De Simone G Chem Commun (Camb); 2012 Sep; 48(70):8838-40. PubMed ID: 22836518 [TBL] [Abstract][Full Text] [Related]
24. Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors. Tauro M; Loiodice F; Ceruso M; Supuran CT; Tortorella P Bioorg Med Chem Lett; 2014 Jun; 24(12):2617-20. PubMed ID: 24813742 [TBL] [Abstract][Full Text] [Related]
25. Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors. Sheppard GS; Florjancic AS; Giesler JR; Xu L; Guo Y; Davidsen SK; Marcotte PA; Elmore I; Albert DH; Magoc TJ; Bouska JJ; Goodfellow CL; Morgan DW; Summers JB Bioorg Med Chem Lett; 1998 Nov; 8(22):3251-6. PubMed ID: 9873712 [TBL] [Abstract][Full Text] [Related]
26. Recent advances in the discovery of zinc-binding motifs for the development of carbonic anhydrase inhibitors. Winum JY; Supuran CT J Enzyme Inhib Med Chem; 2015 Apr; 30(2):321-4. PubMed ID: 24939097 [TBL] [Abstract][Full Text] [Related]
27. Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: hydroxamic acid analogs. Gupta SP; Kumaran S Med Chem; 2006 May; 2(3):243-50. PubMed ID: 16948470 [TBL] [Abstract][Full Text] [Related]
28. A quantitative structure-activity relationship study on some novel series of hydroxamic acid analogs acting as matrix metalloproteinase inhibitors. Kumaran S; Gupta SP Med Chem; 2007 Mar; 3(2):167-73. PubMed ID: 17348854 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812 [TBL] [Abstract][Full Text] [Related]
30. Protease inhibitors - part 5. Alkyl/arylsulfonyl- and arylsulfonylureido-/arylureido- glycine hydroxamate inhibitors of Clostridium histolyticum collagenase. Scozzafava A; Supuran CT Eur J Med Chem; 2000 Mar; 35(3):299-307. PubMed ID: 10785556 [TBL] [Abstract][Full Text] [Related]
31. Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality. Fray MJ; Burslem MF; Dickinson RP Bioorg Med Chem Lett; 2001 Feb; 11(4):567-70. PubMed ID: 11229773 [TBL] [Abstract][Full Text] [Related]
32. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases. Sylte I; Dawadi R; Malla N; von Hofsten S; Nguyen TM; Solli AI; Berg E; Adekoya OA; Svineng G; Winberg JO PLoS One; 2018; 13(8):e0200237. PubMed ID: 30075004 [TBL] [Abstract][Full Text] [Related]
34. Hydroxamic acids as matrix metalloproteinase inhibitors. Verma RP Exp Suppl; 2012; 103():137-76. PubMed ID: 22642192 [TBL] [Abstract][Full Text] [Related]
35. Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review. Yadav RK; Gupta SP; Sharma PK; Patil VM Curr Med Chem; 2011; 18(11):1704-22. PubMed ID: 21428880 [TBL] [Abstract][Full Text] [Related]
36. A combined molecular modeling study on gelatinases and their potent inhibitors. Xi L; Du J; Li S; Li J; Liu H; Yao X J Comput Chem; 2010 Jan; 31(1):24-42. PubMed ID: 19412908 [TBL] [Abstract][Full Text] [Related]
37. MMP-2 selectivity in hydroxamate-type inhibitors. Serra P; Bruczko M; Zapico JM; Puckowska A; Garcia MA; Martin-Santamaria S; Ramos A; de Pascual-Teresa B Curr Med Chem; 2012; 19(7):1036-64. PubMed ID: 22257051 [TBL] [Abstract][Full Text] [Related]
38. Hydroxamate derivatives of substrate-analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases. Krumme D; Wenzel H; Tschesche H FEBS Lett; 1998 Oct; 436(2):209-12. PubMed ID: 9781680 [TBL] [Abstract][Full Text] [Related]
39. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871 [TBL] [Abstract][Full Text] [Related]
40. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2. Jani M; Tordai H; Trexler M; Bányai L; Patthy L Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]